Basking Biosciences Inc

Biotechnology, Pharma, Neurology, Biotech, Cardiovascular
Founded in 2019
Columbus, Ohio
http://www.baskingbiosciences.com
None

About Basking Biosciences Inc

Basking is developing the first in class agent (BB-031) targeting von Willebrand Factor (VWF) along with a direct acting reversal agent (BB-025) to immediately the pharmacological effect of BB-031 in the event of bleeding. BB-031 is an RNA aptamer optimized for rapid onset of action and short duration of effect. Basking will initiate a Phase 2 trial in acute ischemic stroke in late 2023 and is exploring further application in pulmonary embolism in preclinical studies. The technology is based on two decades of translational research on RNA aptamers as therapeutic agents for cardiovascular diseases.

Company Metrics

  • Employees: 1-10
  • Monthly Visits: None
  • Tech Stack: None active products

Financial Information

  • Estimated Revenue: Less than $1M
  • Total Funding: 5.4M None
  • Last Funding: 5.4M None (None)
  • Funding Status: None

Technology Stack

Basking Biosciences Inc actively uses None products in their tech stack.

Market Presence

Industries: Biotechnology, Pharma, Neurology, Biotech, Cardiovascular

Headquarters: Columbus, Ohio